Fusion Pharmaceuticals Inc. (FUSN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus ...
Fusion Pharmaceuticals Inc. (FUSN) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.45 per share a year ago. These ...
This analysis is by Bloomberg Intelligence Thematic Strategist Mike Dennis. It appeared first on the Bloomberg Terminal. Achievement of net energy — where energy produced exceeds the energy used — via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback